Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.
CDKY709A12101C
Phase 1 other active
Quick answer
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. for Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma
- Phase
- Phase 1
- Modality
- other
- Status
- active